<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126668</url>
  </required_header>
  <id_info>
    <org_study_id>CM082-CA-I-106</org_study_id>
    <nct_id>NCT04126668</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers</brief_title>
  <official_title>A Pharmacokinetic Study in Chinese Healthy Male and Female Volunteers to Investigate the Effect of Food on the Pharmacokinetics of CM082 Tablet.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnewPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AnewPharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of
      CM082 tablet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of
      CM082 tablet in Chinese Healthy Volunteers. In addition, the safety of CM082 tablet in
      Chinese Healthy Volunteers who with High-fat meal or fasting state will also be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Actual">January 16, 2020</completion_date>
  <primary_completion_date type="Actual">January 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of CM082</measure>
    <time_frame>pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)</time_frame>
    <description>The effect of food on Cmax after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of CM082</measure>
    <time_frame>pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)</time_frame>
    <description>The effect of food on AUC after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum concentration（Tmax）of CM082</measure>
    <time_frame>pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)</time_frame>
    <description>The effect of food on Tmax after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life（T1/2）of CM082</measure>
    <time_frame>pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)</time_frame>
    <description>The effect of food on T1/2 after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of adverse events</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 months</time_frame>
    <description>Percentage of adverse events as assessed by CTCAE v4.03</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Advanced Malignant Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Period 1: fasted control → Period 2: fed control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: administration of CM082 200 mg at 7:30am, without the breakfast；Period 2: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 1: fed control → Period 2: fasted control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of CM082 200 mg at 7:30am, without the breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM082 with fed or fasting</intervention_name>
    <description>The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.</description>
    <arm_group_label>Period 1: fasted control → Period 2: fed control</arm_group_label>
    <arm_group_label>Period 1: fed control → Period 2: fasted control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: 18 - 45 years;

          -  sex: male and female;

          -  body weight: Male ≥ 50 kg,female ≥ 45 kg, body mass index BMI (weight (kg)/height 2
             (m2)) between 19-26 kg/m2 (including border);

          -  Healthy as judged by the investigator/subinvestigator based on the results of physical
             examinations and all lab tests;

          -  Abstinence or physical contraception approved by researchers must be approved during
             and within three months after the trial is completed; and no sperm and egg donation
             plan is available；

          -  Written informed consent;

        Exclusion Criteria:

          -  Received any investigational drugs within 14 days before the screening test;

          -  Donated 200 mL of whole blood within 30 days before the screening test,or donated 200
             mL of whole blood during the study or within 30 days after completion of the study;

          -  Females who are lactating, pregnant, potentially child-bearing, or willing to get
             pregnant during the study period;

          -  History of drug or food allergies;

          -  Abnormal blood pressure or pulse，Abnormal laboratory tests;

          -  Participated in other clinical trials within 3 months before screening;

          -  Smoking and drinking within 3 months before screening or test results of smoke,
             alcohol, and drug abuse are positive;

          -  Positive for HBsAg, Hepatitis C virus (HCV) antibody, HIV antibody or syphilis
             antibody;

          -  Clinically apparent disease/infection within 1 month before screening;

          -  The researchers determined that there were other conditions that were not suitable for
             the trial;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zourong ruan</last_name>
    <role>Study Chair</role>
    <affiliation>the Second Affiliated Hospital of Zhejiang University Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The 1st Phase Clinical Research Center of the Second Affiliated Hospital of Zhejiang University Medical College</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>311009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

